Peregrine to Report Fourth Quarter and Fiscal Year 2012 Financial Results After Market Close on July 16, 2012

Peregrine to Present at JMP Securities Healthcare Conference July 12, 2012 at 9:30 AM EDT

Peregrine Completes Patient Enrollment in Randomized Phase II Pancreatic Cancer Trial for Bavituximab

Avid Bioservices Announces Addition of Novel Bacteriophage Production System at Upcoming BIO Conference as Part of a Collaboration With Phage Pharmaceuticals

Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer

Researchers Present Data Highlighting Potential of Peregrine's PS-Targeting Antibodies to Treat Ocular Herpes Infections and Macular Degeneration

Peregrine's Novel PS-Targeting Technology Platform to Be Highlighted at The New York Academy of Sciences Symposium on May 1, 2012

Promising Clinical Data in Breast and Liver Cancers Further Expand the Broad Therapeutic Potential of Peregrine's Bavituximab

Peregrine Launches PS-Targeting Clinical Imaging Program

AVID Bioservices Highlights Antibody Engineering, Expression and Bioassay Expertise at AACR